Low Calorie Diet for Obesity
(SEV Trial)
Trial Summary
What is the purpose of this trial?
This trial aims to understand why some people with obesity develop conditions like type 2 diabetes while others do not. Researchers will study tiny particles called small extracellular vesicles (sEVs) from different groups of people to see how they affect insulin use in cells and mice. The findings could lead to new treatments for obesity-related health issues.
Will I have to stop taking my current medications?
The trial requires that you do not take medications that could affect the study outcome measures, so you may need to stop certain medications. It's best to discuss your specific medications with the study team.
What data supports the effectiveness of the low-calorie diet treatment for people with metabolically unhealthy obesity?
Research shows that very low-calorie diets (VLCDs) can lead to significant weight loss, with patients losing about 20 kg in 12 to 16 weeks and maintaining a portion of this loss over time. Additionally, VLCDs have been shown to improve insulin sensitivity in obese patients with type 2 diabetes, suggesting potential benefits for metabolically unhealthy obesity.12345
Is a low-calorie diet safe for treating obesity?
Low-calorie diets (LCDs) and very-low-calorie diets (VLEDs) are generally safe for treating obesity, with minor side effects that are self-limiting. They have been shown to improve metabolic and cardiovascular health, though one serious adverse event, cholecystitis (inflammation of the gallbladder), was reported in a study. Overall, these diets are well-tolerated and can be a safe option for weight loss.56789
How does a low calorie diet treatment for metabolically unhealthy obesity differ from other treatments?
A low calorie diet treatment for metabolically unhealthy obesity is unique because it involves alternating between moderate and very low calorie intake, which can be more effective and less monotonous than traditional diets. This approach has shown success in difficult cases of obesity and is well accepted by patients, offering a structured yet flexible method for weight loss.510111213
Research Team
Dmitri Samovski, PhD
Principal Investigator
Washington University School of Medicine
Eligibility Criteria
This trial is for adults with obesity and signs of insulin resistance, such as high blood sugar or HbA1c levels. Participants should have a BMI between 30.0-50.0 kg/m2 if they're obese, or 18.5-24.9 kg/m2 if lean and healthy. They shouldn't have diabetes, liver diseases other than NAFLD, engage in regular exercise, drink excessively, take interfering medications, or be pregnant/lactating.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Testing
Baseline testing of metabolically healthy lean, metabolically healthy obese, and metabolically unhealthy obese participants
Dietary Intervention
Low calorie diet intervention for metabolically unhealthy obese participants to achieve ~10% weight loss
Follow-up
Participants are monitored for changes in insulin sensitivity and other metabolic parameters after intervention
Treatment Details
Interventions
- People with Metabolically Unhealthy Obesity (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
David H. Perlmutter
Washington University School of Medicine
Chief Executive Officer since 2015
MD from Washington University School of Medicine
Paul Scheel
Washington University School of Medicine
Chief Medical Officer since 2022
MD from Washington University School of Medicine